RecruitingNCT04373317
Pimavanserin or quetiapine for psychosis in Parkinson’s disease
About this title
Read the official source — NCT04373317Medication studyAges 40+United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: from 40 years.
What will I do during this study?
Participants are randomly assigned to pimavanserin or quetiapine for an eight-week treatment phase. The quetiapine dose is adjusted during the first part of treatment; pimavanserin is given at a fixed daily dose.
- Listed locations
- Tucson and 23 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 24, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 358
- Sponsor
- VA Office of Research and Development
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 40 Years
- Official registry ID
- NCT04373317
- Official title
Show the full official title
CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Tucson · Loma Linda · Palo Alto
20 more locations
- San Francisco
- West Los Angeles
- Aurora
- Gainesville
- Hines
- Lexington
- Ann Arbor
- Minneapolis
- St Louis
- Albuquerque
- Syracuse
- Asheville
- Cleveland
- Portland
- Philadelphia
- Nashville
- Houston
- San Antonio
- Richmond
- Seattle
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is VA Office of Research and Development, a government agency.
Does this study involve medication?
Yes. The study involves medication, including Pimavanserin and Quetiapine.
Who can participate?
Listed age limits: from 40 years.
Is this study still recruiting?
The registry lists this study as recruiting.
